Triple-action cancer immunotherapy eradicates entire tumours in trial, Guardian reports
An international clinical trial showing that a triple-action cancer immunotherapy can fully eradicate tumours in patients whose disease had become resistant to chemotherapy and immunotherapy was reported by The Guardian. The trial, spanning 11 countries, delivered a treatment combining three distinct immune-activation mechanisms in a single injection to patients who had failed two or more standard treatments. Results were presented at the American Society of Clinical Oncology (ASCO) annual meeting and described by independent specialists as showing 'response rates without precedent'.
The trial covered patients with advanced melanoma, lung cancer and several sarcoma types. The 158 enrolled patients had all previously declined or failed at least two standard treatments. According to The Guardian, approximately 28 percent of patients in the trial showed a 'complete response' — that is, tumours that had disappeared on imaging. The typical complete-response rate for traditional second- and third-line therapies in such patient populations is below 8 percent.
The triple mechanism of the immunotherapy targets three separate immune pathways simultaneously: it blocks the CTLA-4 and PD-1 checkpoint inhibitors while activating dendritic cells through a third agent. The co-principal investigator of the trial, Dr Ryan Sullivan, an oncologist at Massachusetts General Hospital, told the press 'we believe that activating these mechanisms simultaneously gives the tumour-recognising T-cells a multi-signal that classical single-checkpoint therapy does not deliver'.
The significance of the trial results comes from the fact that this patient cohort had effectively exhausted its options. According to The Guardian's coverage of independent analysis, the majority of melanoma patients in whom classical checkpoint therapy fails also fail to respond to chemotherapy, with typical median survival measured in months. In that context, the triple-therapy group showed a median progression-free survival of 8.5 months, compared with 3.2 months in the standard-treatment control group.
Still, important reservations about future use of the therapy have surfaced. Per The Guardian, the safety profile of the triple combination was more severe than that of single-checkpoint therapy. Approximately 65 percent of patients in the trial experienced grade 3 or 4 immune-related adverse events — particularly involving endocrine organs. That rate is nearly double what is observed with classical checkpoint therapy. Should the therapy be approved, identifying which patient groups can tolerate the risk profile will be a key clinical question.
The two pharmaceutical sponsors of the trial (BioNTech and Pfizer, conducting the work jointly) announced that phase 3 studies have already begun in recent months, with data expected to be evaluable by mid-2027. Dr Richard Pazdur, director of the FDA's Office of Oncologic Diseases, said in remarks at ASCO that the trial was 'an important step, but we need to watch how the safety profile behaves across a broader patient universe'.
The Guardian's analysis framed the trial as the long-awaited fulfilment of a 'combination approach' to advanced cancer treatment. Over the past decade, checkpoint therapies that succeeded in cancer care have produced genuine responses in roughly 20 to 30 percent of patients; this triple mechanism appears to more than double that response rate.
Dr Sarah Larson, head of health economics at the US National Cancer Institute, told The Guardian that the therapy's cost has not been finalised but is expected to exceed that of checkpoint therapies (around 12,000 dollars per month). Given the average 8-month treatment duration of the triple therapy, per-patient cost is estimated above 100,000 dollars. For insurers and public health systems, this will require a reassessment of advanced-cancer policy.
Professor Sarah Welsh, an oncology scientist at King's College London, told The Guardian that the trial is 'a productive but cautious moment to interpret'. Welsh added, 'we are not treating the patient — we are treating the immune system; that is a different calculation'. The development of biomarker-based tests to identify which patient groups will benefit has been highlighted as a research priority for the next two years.
This article is not medical advice. Readers with a cancer diagnosis or seeking treatment options should consult their oncology team and clinical-research centres. Over the coming months, whether the FDA opens an accelerated review will be the key regulatory signal determining the future role of triple cancer immunotherapy. The Guardian's coverage noted that patient groups and clinicians will continue to follow the trial's long-term data at upcoming ASCO meetings.